Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to…
– Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into…
– Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM – – Completed Public Equity Offering…
Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in…
-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed…
— Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults…
Clinical Execution of Lead GeneTAC™ Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust…
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to…
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet…
PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical…